How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of age, disability, gender reassignment, pregnancy and maternity, race, religion or belief, sex or sexual orientation?
The content on this page is not current guidance and is only for the purposes of the consultation process.

1 Recommendations

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about adagrasib

Conditional marketing authorisation indication

2.1

Adagrasib (Krazati, Bristol Myers Squibb) is indicated for 'the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and have progressive disease after prior therapy with, or intolerance to, platinum-based chemotherapy and/or anti-PD-1/PD-L1 immunotherapy'.

Price

2.3

The list price of adagrasib tablets is confidential until published by the Department of Health and Social Care.

2.4

The company has a commercial arrangement, which would have applied if adagrasib had been recommended.

Carbon Reduction Plan

2.5

Information on the Carbon Reduction Plan for UK carbon emissions for Bristol Myers Squibb will be included here when guidance is published.